（嘉事堂公告） 近日，嘉事堂发布公告称，2026年2月2日，公司股东光大实业、光大健康与中国北京同仁堂（集团）有限责任公司 （以下简称"同仁堂集团"）签署了《股份转让协议》，协议约定光大实业、光大健康分别将其持有的公司41,180,805股 股份、41,876,431股股份转让给同仁堂集团。本次交易完成后，公司控股股东将变更为同仁堂集团，实际控制人将变 更为北京市人民政府国有资产监督管理委员会。 ...

格隆汇2月5日丨南京医药(600713.SH)在互动平台表示，公司尚未在物流仓储与智慧药房场景应用介入 机器人研发生产。 ...

（文章来源：证券日报） 证券日报网讯 2月4日，英特集团在互动平台回答投资者提问时表示，截至2026年1月30日，公司股东户 数为30780户。 ...

香港联交所最新数据显示，1月30日，摩根大通增持国药控股(01099)130.4617万股，每股作价20.8553港 元，总金额约为2720.82万港元。增持后最新持股数目约为6738.7万股，持股比例为5.02%。 ...

智通财经APP获悉，香港联交所最新数据显示，1月30日，摩根大通增持国药控股(01099)130.4617万 股，每股作价20.8553港元，总金额约为2720.82万港元。增持后最新持股数目约为6738.7万股，持股比 例为5.02%。 ...

Market Overview - The pharmaceutical commercial sector increased by 1.34% on February 4, with Yifeng Pharmacy leading the gains [1] - The Shanghai Composite Index closed at 4102.2, up 0.85%, while the Shenzhen Component Index closed at 14156.27, up 0.21% [1] Stock Performance - Yifeng Pharmacy (603939) closed at 24.76, up 4.96% with a trading volume of 180,700 shares [1] - Dazhenlin (603233) rose by 3.27% to 19.88, with a trading volume of 82,100 shares and a transaction value of 161 million [1] - Fuzhong (002462) increased by 2.80% to 16.86, with a trading volume of 337,400 shares [1] - Login Medical (002788) saw a 2.60% rise to 16.60, with a trading volume of 367,300 shares [1] - Other notable stocks include Nanjing Pharmaceutical (600713) up 2.03% and Jianzhijia (605266) up 1.95% [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 18.375 million from institutional investors, while retail investors saw a net outflow of 34.4782 million [2] - Conversely, speculative funds recorded a net inflow of 52.8532 million [2] Individual Stock Capital Flow - Luyan Pharmaceutical (002788) had a net inflow of 42.3085 million from institutional investors, while retail investors faced a net outflow of 72.3406 million [3] - Yifeng Pharmacy (603939) saw a net inflow of 20.1487 million from institutional investors and a net outflow of 57.1720 million from retail investors [3] - Huaren Health (301408) had a net inflow of 12.3779 million from institutional investors, with a net outflow of 15.7068 million from retail investors [3]

Core Viewpoint - The acquisition of Jiasitang by Tongrentang Group marks a strategic move to enhance its pharmaceutical commercial segment and leverage Jiasitang's hospital channel resources to expand product sales and market share [1][2] Group 1: Acquisition Details - Jiasitang announced that its shareholders, Everbright Health and Everbright Industry, signed a share transfer agreement with Tongrentang Group, transferring 41.18 million shares and 41.87 million shares respectively at a price of 17.59 yuan per share, totaling approximately 1.461 billion yuan [1] - After the transaction, Tongrentang Group will hold 83.06 million shares of Jiasitang, representing a 28.48% stake, making it the controlling shareholder, while Everbright Industry and Everbright Health will exit completely [1] - The actual controller of Jiasitang will change from China Everbright Group to Beijing State-owned Assets Supervision and Administration Commission [1] Group 2: Market Reaction - Following the news of the acquisition, Jiasitang's stock hit the daily limit on February 4, before slightly retreating, closing up about 3% at 16.87 yuan per share [1] Group 3: Company Performance - Jiasitang's performance has been declining, with net profit dropping from 297 million yuan in 2022 to 161 million yuan in 2024, reflecting year-on-year declines of 16.09%, 15.79%, and 35.75% respectively [2] - For the first three quarters of 2025, Jiasitang reported revenue of 14.459 billion yuan, a year-on-year decrease of 21.80%, and a net profit of 141 million yuan, down 38.81% year-on-year [2] - The company's gross margin has fallen to 6.28% [2] Group 4: Tongrentang Group Overview - Tongrentang Group's business focuses on the production and sales of traditional Chinese medicine, forming a comprehensive health industry chain supported by pharmaceutical manufacturing, health maintenance, medical care, retail, and international pharmaceutical operations [2] - Tongrentang Group currently has three listed companies, and if the acquisition of Jiasitang is successful, it will add a fourth listed entity [2] - The core asset of Tongrentang is its traditional Chinese medicine business, which includes well-known products like Angong Niuhuang Wan and Niuhuang Qingxin Wan, although its performance has also faced challenges, with total revenue dropping to 13.308 billion yuan in the first three quarters of the previous year, a year-on-year decline of 3.7% [2]

2025年半年报显示，期内公司实现营业收入96.99亿元，实现净利润1.63亿元。 其中，在药品销售方面，嘉事堂是北京市医药商业龙头企业，北京基药主要配送商之一，服务北京二三 级医院300多家，覆盖率达99%。 在医疗器械方面，嘉事堂拥有心脑血管等高值耗材细分市场占优的渠道和终端网络，形成全国布局，重 点区域为长三角、粤港澳大湾区、京津冀、西南、西北区域，与2100多家医院建立终端销售渠道。 2月4日早间开盘，嘉事堂股价复牌。截至发稿时间，每股报价17.02元，涨幅3.78%，总市值49.62亿 元。 消息面上，2月3日晚间，嘉事堂发布公告称，公司股东光大实业、光大健康与同仁堂集团签署了《股份 转让协议》，协议约定光大实业、光大健康分别将其持有的公司约4118万股股份、4187.6万股股份转让 给同仁堂集团。转让价格为人民币17.59元/股，转让价款总计为人民币14.6亿元。 本次交易完成后，公司控股股东将变更为同仁堂集团，实际控制人将变更为北京市人民政府国有资产监 督管理委员会。 公告表示，本次协议转让尚需经主管国有资产监督管理部门批准、通过国家市场监督管理总局经营者集 中反垄断审查、通过深圳证券交易所合规 ...

2月3日晚，深交所主板上市公司嘉事堂公告表示，2月2日公司股东与中国北京同仁堂（集团） 有限责任公司（简称"同仁堂集团"）签署股份转让协议， 约定将光大实业、光大健康持有的公司股份以14.6亿元转让给同仁堂集团。 本次交易完成后，嘉事堂公司控股股东将变更为同仁堂集团，实际控制人将变更为北京市国资委。 公告显示，此次股份转让价格为17.59元/股，转让价款总计为14.6亿元。其中，光大健康将其持有的公司41876431股股份（占公司总股本的14.36%）转让 给同仁堂集团，转让价款为736606421.29元；光大实业将其持有的公司41180805股股份（占公司总股本的14.12%）转让给同仁堂集团，转让价款为 724370359.95元。 | 股东名称 | 本次交易前 | | 本次交易后 | | | --- | --- | --- | --- | --- | | | 持股数量(股) | 持股比例 | 持股数量(股) | 持股比例 | | 光大健康 | 41,876,431 | 14. 36% | | | | 光大实业 | 41,180,805 | 14. 12% | | | | 同仁堂集团 | | | 83, ...

Company News - Guizhou Moutai repurchased 329,800 shares in January, accounting for 0.0263% of the total share capital, with a total payment of 451 million yuan. By the end of January, the total repurchased shares reached 416,900, accounting for 0.0333% of the total share capital, with a total payment of 571 million yuan (excluding transaction fees) [3] - Contemporary Amperex Technology Co., Ltd. repurchased 15,990,800 A-shares by January 31, accounting for 0.3628% of the total A-shares, with a maximum transaction price of 317.63 yuan/share and a minimum of 231.50 yuan/share, totaling 4.386 billion yuan (excluding transaction fees) [3] - Zhiyang Innovation announced plans to acquire control of Lingming Photon through stock issuance, convertible bonds, and cash payments, which is expected to constitute a major asset restructuring. The stock will be suspended from trading starting February 4 for no more than five trading days [3] - Kailong High-Tech plans to acquire 70% of Shenzhen Jinwangda Electromechanical Co., Ltd. through stock issuance and cash payment, with the transaction price yet to be determined. This acquisition is expected to constitute a major asset restructuring, and the stock will resume trading on February 4 [4] - Han Jian Heshan intends to acquire 99.9978% of Liaoning Xingfu New Materials Co., Ltd. through stock issuance and cash payment, with the transaction price still to be finalized. This transaction is expected to constitute a major asset restructuring and will not result in a restructuring listing, with the stock resuming trading on February 4 [4] - ST Cube announced a stock suspension for self-examination due to abnormal price fluctuations, with the stock resuming trading on February 4. The stock price has increased by 188.06% over eight trading days, raising concerns about market sentiment and potential risks of rapid price declines [5] - Jiashitang announced a share transfer agreement with Beijing Tongrentang Group, resulting in a change of controlling shareholder to Tongrentang Group and the actual controller to the State-owned Assets Supervision and Administration Commission of Beijing Municipal Government. The stock will resume trading on February 4 [6] - Juguang Technology's stock price has deviated significantly, with a cumulative increase of over 30% in three consecutive trading days. Despite the recent improvement in the optical communication industry, the revenue from this sector only accounted for about 7% of the company's total revenue as of Q3 2025 [6] Industry News - The People's Bank of China conducted a liquidity injection of 800 billion yuan through reverse repos on February 3, with various monetary policy tools showing net injections of 700 billion yuan for medium-term lending facilities and 1.744 trillion yuan for mortgage supplementary loans in January [2] - The Ministry of Commerce announced plans to optimize the implementation of appliance recycling and subsidy policies in 2026, with sales of six categories of home appliances and four categories of digital and smart products exceeding 15 million units and sales revenue nearing 59 billion yuan in January [2] - The Ministry of Industry and Information Technology emphasized the need to promote the construction of future industry pilot zones and enhance technological supply in key areas such as 6G, quantum technology, and hydrogen energy [2] - CITIC Securities reported that the introduction of capacity electricity pricing policies will be crucial for the independent development of energy storage, while the nuclear power market may face price impacts due to the release of lower limits on thermal power prices [7]